首页> 美国卫生研究院文献>Interdisciplinary Toxicology >Advances in acute toxicity testing: strengths weaknesses and regulatory acceptance
【2h】

Advances in acute toxicity testing: strengths weaknesses and regulatory acceptance

机译:急性毒性测试的进展:优势劣势和监管认可

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Safety assessment of chemicals, pharmaceuticals, food and food ingredients, cosmetics, industrial products is very crucial prior to their approval for human uses. Since the commencement of toxicity testing (about 500 years ago, since 1520), significant advances have been made with respect to the 3Rs (reduction, refinement and replacement) alternative approaches. This review is focused on the update in acute systemic toxicity testing of chemicals. Merits and demerits of these advances were also highlighted. Traditional LD50 test methods are being suspended while new methods are developed and endorsed by the regulatory body. Based on the refinement and reduction approaches, the regulatory body has approved fixed dose procedure (FDP), acute toxic class (ATC) method and up and down procedure (UDP) which involves few numbers of animals. In terms of replacement approach, the regulatory body approved 3T3 neutral red uptake (NRU), the normal human keratinocyte (NHK), and the 3T3 neutral red uptake (NRU) phototoxicity test for acute phototoxicity. However, other promising replacement alternatives such as organ on chip seeded with human cells for acute systemic toxicity and 3T3 neutral red uptake (NRU) cytotoxicity test for identifying substances not requiring classification, as well as the in silico approaches are yet to receive regulatory approval. With this backdrop, a collaborative effort is required from the academia, industries, regulatory agencies, government and scientific organizations to ensure speedily regulatory approval of the prospective alternatives highlighted.
机译:化学品,药品,食品和食品成分,化妆品,工业产品的安全评估在批准用于人类之前是至关重要的。自开始毒性测试(大约从500年前的1520年开始)以来,在3R(还原,精制和替代)替代方法方面已取得了重大进展。这项审查的重点是化学品的急性全身毒性试验的更新。这些进展的优缺点也被强调。传统的LD50测试方法正在暂停,而监管机构正在开发和认可新的方法。基于改进和减少方法,监管机构已批准了固定剂量程序(FDP),急性毒性分类(ATC)方法和上下程序(UDP),涉及的动物数量很少。在替代方法方面,监管机构批准了3T3中性红吸收(NRU),正常人角质形成细胞(NHK)和3T3中性红吸收(NRU)光毒性测试用于急性光毒性。但是,其他有希望的替代替代品,例如植入人细胞的片上器官,可用于急性全身毒性和3T3中性红吸收(NRU)细胞毒性测试,以识别不需要分类的物质,以及计算机方法也尚未获得监管部门的批准。在这种背景下,需要学术界,行业,监管机构,政府和科学组织的共同努力,以确保迅速对突出显示的潜在替代方案进行监管批准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号